From Earlier: FDA Approves Lilly's Jentadueto Tablets for the Treatment of Adult Patients with Type 2 Diabetes
Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) yesterday announced the U.S. Food and Drug Administration has approved Jentadueto™ (linagliptin/metformin hydrochloride) tablets, a new tablet combining the dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, and metformin. JENTADUETO provides a new, single-tablet treatment option, taken twice-daily, for patients who need to control their blood sugar. Linagliptin (5 mg, once-daily) is marketed in the U.S. as Tradjenta™ (linagliptin) tablets.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.